Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Laekna Inc.
Industry Sector: HealthTechnology
CEO: Xiang Yang Lu, PhD
Number Of Employees: 89
Enterprise Value: $805,138,616
PE Ratio: -15.12
Exchange/Ticker 1: HKEX:2105
Exchange/Ticker 2: N/A
Latest Market Cap: $652,704,429
BioCentury | Dec 7, 2024
Finance
Revolution, Janux prep for next steps with follow-on cash
In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial
BioCentury | Sep 27, 2023
Deals
Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front
The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape
BioCentury | Jun 29, 2023
Product Development
June 29 Quick Takes: Disclosure of impropriety jeopardizes integrity of BioXcel’s trial
Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures
BioCentury | May 19, 2022
Product Development
May 18 Quick Takes: Enanta tumbles after hours after missing RSV endpoint
Plus: House E&C passes user fee bill and updates from Hengrui, Laekna, Prenetics, Enanta and more
BioCentury | Mar 29, 2022
Management Tracks
Rangwala to be CMO at Karyopharm
Plus Jones becomes CFO at Sense, and updates from Enzo, Dice and more
BioCentury | Jun 29, 2019
Finance
New fund to expand Anlong’s tool kit for early stage deals
With a new U.S. dollar fund Anlong aims to fund Chinese companies looking to list in Hong Kong or overseas
BioCentury | Sep 14, 2018
Emerging Company Profile
Laekna’s jumping off place
Why Laekna Therapeutics opted to start with a trio of Novartis compounds
Items per page:
1 - 10 of 10